Abstract
The identification of therapeutic immunomodulatory mesenchymal stromal cells (MSC) with specific homing capabilities has simultaneously contributed to the potential development of powerful cellular immune therapies, with applications for a variety of inflammatory associated diseases. MSC have the ability to directly abrogate T cell, macrophage, dendritic cell (DC), neutrophil, and B cell pro-inflammatory functions. Specifically, T cell, macrophage, and DC MSC-mediated immunosuppression results in the adoption of phenotypes indicative of type II anti-inflammatory functional cells. These findings collectively suggest that MSC directly combat inflammation by controlling endogenous immune mechanisms. In this chapter, the molecular/cellular mechanisms governing these phenomena are discussed for each MSC-immune cell interaction. Furthermore, MSC homing mechanisms are discussed, highlighting our current understanding of the modes and limitations of MSC direct implantation modalities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gnecchi M et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11(4):367–368
Parekkadan B et al (2011) Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b(+) splenocytes. Gastroenterology 140(3):966–975 e4
Parekkadan B et al (2007) Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2(9):e941
Kunter U et al (2006) Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 17(8):2202–2212
Panes J, Benitez-Ribas D, Salas A (2011) Mesenchymal stem cell therapy of Crohn’s disease: are the far-away hills getting closer? Gut 60(6):742–744
Galindo LT et al (2011) Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int 2011:564089
Zappia E et al (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5):1755–1761
Zheng ZH et al (2008) Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology 47(1):22–30
Kassis I et al (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65(6):753–761
NIH (2011) Mesenchymal stem cell clinical studies [cited 2011; Available from: www.clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells]
Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117
Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076–1084
Maitra B et al (2004) Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33(6):597–604
Le Blanc K et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579–1586
Le Blanc K et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441
Glennie S et al (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7):2821–2827
Constantin G et al (2009) Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27(10):2624–2635
Bai L et al (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57(11):1192–1203
Gordon D et al (2010) Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 69(11):1087–1095
Gonzalez-Rey E et al (2010) Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 69(1):241–248
Gonzalez MA et al (2009) Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136(3):978–989
Mougiakakos D et al (2011) The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117(18):4826–4835
Maccario R et al (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90(4):516–525
Prevosto C et al (2007) Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92(7):881–888
Najar M et al (2009) Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11(5):570–583
Beyth S et al (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105(5):2214–2219
Opitz CA et al (2009) Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27(4):909–919
Meisel R et al (2011) Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25(4):648–654
DelaRosa O et al (2009) Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng A 15(10):2795–2806
Ryan JM et al (2007) Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149(2):353–363
Zhao ZG et al (2008) Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunol Invest 37(7):726–739
Najar M et al (2010) Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cell Immunol 264(2):171–179
Yanez R et al (2010) Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 316(19):3109–3123
Lanz TV et al (2010) Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev 19(5):657–668
Ren G et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2(2):141–150
Ren G et al (2009) Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27(8):1954–1962
Nasef A et al (2007) Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84(2):231–237
Selmani Z et al (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3+ regulatory T cells. Stem Cells 26(1):212–222
Sioud M et al (2011) Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 38(2):385–390
Sioud M et al (2010) Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 71(4):267–274
Gur-Wahnon D et al (2007) Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol 35(3):426–433
Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815–1822
Yan Y et al (2010) IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185(10):5953–5961
Stockinger B, Veldhoen M, Martin B (2007) Th17 T cells: linking innate and adaptive immunity. Semin Immunol 19(6):353–361
Ghannam S et al (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185(1):302–312
Duffy MM et al (2011) Mesenchymal stem cell inhibition of T-helper 17 differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 41(10):2840–2851
Tatara R et al (2011) Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13(6):686–694
Park MJ et al (2011) Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 63(6):1668–1680
Rafei M et al (2009) Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 182(10):5994–6002
Guo Z et al (2009) Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur J Immunol 39(10):2840–2849
Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469
Vivier E et al (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510
Spaggiari GM et al (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107(4):1484–1490
Spaggiari GM et al (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3):1327–1333
Rasmusson I et al (2003) Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76(8):1208–1213
Sotiropoulou PA et al (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1):74–85
Neumann H et al (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25(6):313–319
Friese MA, Fugger L (2009) Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 66(2):132–141
Rasmusson I et al (2007) Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 82(4):887–893
Karlsson H et al (2008) Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112(3):532–541
Traggiai E et al (2008) Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26(2):562–569
Corcione A et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107(1):367–372
Tabera S et al (2008) The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93(9):1301–1309
Asari S et al (2009) Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 37(5):604–615
Schena F et al (2010) Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 62(9):2776–2786
Augello A et al (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35(5):1482–1490
Youd M et al (2010) Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 161(1):176–186
Kigerl KA et al (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29(43):13435–13444
Kanno S et al (2001) Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104(8):934–938
van Reyk DM, Jessup W (1999) The macrophage in atherosclerosis: modulation of cell function by sterols. J Leukoc Biol 66(4):557–561
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3(1):23–35
Kim J, Hematti P (2009) Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 37(12):1445–1453
Cutler AJ et al (2010) Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol 185(11):6617–6623
Maggini J et al (2010) Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 5(2):e9252
Zhang QZ et al (2010) Human gingiva-derived mesenchymal stem cells elicit polarization of M2 macrophages and enhance cutaneous wound healing. Stem Cells 28(10):1856–1868
Barminko J et al (2011) Encapsulated mesenchymal stromal cells for in vivo transplantation. Biotechnol Bioeng 108(11):2747–2758
Nemeth K et al (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15(1):42–49
Chen L et al (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3(4):e1886
Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10(6):427–439
Faurschou M, Borregaard N (2003) Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5(14):1317–1327
Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6(3):173–182
Ortiz LA et al (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci 104(26):11002–11007
Xu J et al (2007) Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 293(1):L131–L141
Volarevic V et al (2010) Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 43(4):255–263
Pulavendran S, Vignesh J, Rose C (2010) Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol 10(4):513–519
Ajuebor MN et al (1999) Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol 162(3):1685–1691
Bonder CS et al (2005) P-selectin can support both Th1 and Th2 lymphocyte rolling in the intestinal microvasculature. Am J Pathol 167(6):1647–1660
Cassatella M (1998) The neutrophil: one of the cellular targets of interleukin-10. Int J Clin Lab Res 28(3):148–161
Raffaghello L et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26(1):151–162
Cassatella MA et al (2011) Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29(6):1001–1011
Ardavín C et al (2001) Origin and differentiation of dendritic cells. Trends Immunol 22(12):691–700
Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4(12):941–952
Clark GJ et al (2000) The role of dendritic cells in the innate immune system. Microbes Infect 2(3):257–272
Djouad F et al (2007) Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25(8):2025–2032
Jiang X-X et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105(10):4120–4126
Nauta AJ et al (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177(4):2080–2087
Ramasamy R et al (2007) Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83(1):71–76
Spaggiari GM et al (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113(26):6576–6583
Zhang W et al (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13(3):263–271
Wehner R et al (2009) Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells. Haematologica 94(8):1151–1156
Park S-J et al (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173(6):3844–3854
Zhang B et al (2009) Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113(1):46–57
Wang Q et al (2008) Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol 68(6):607–615
Viney JL (1999) Dendritic cell subsets: the ultimate T cell differentiation decision makers? Gut 45(5):640–641
Shi Y et al (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20(5):510–518
Krampera M (2011) Mesenchymal stromal cell “licensing”: a multistep process. Leukemia 25(9):1408–1414
Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1–14
Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81(1):1–5
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384
Ostuni R, Zanoni I, Granucci F (2010) Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 67(24):4109–4134
DelaRosa O, Lombardo E (2010) Modulation of adult mesenchymal stem cells activity by Toll-like receptors: implications on therapeutic potential. Mediat Inflamm 2010:865601. Epub 2010 Jun 14.
Liotta F et al (2008) Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. Stem Cells 26(1):279–289
Pevsner-Fischer M et al (2007) Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109(4):1422–1432
Tomchuck SL et al (2008) Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26(1):99–107
Wang Y et al (2010) TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC–mediated cardioprotection. PLoS One 5(12):e14206
Waterman RS et al (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 5(4):e10088
Haider HK, Ashraf M (2005) Bone marrow stem cell transplantation for cardiac repair. Am J Physiol Heart Circ Physiol 288(6):H2557–H2567
Sadat S et al (2007) The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 363(3):674–679
Sordi V et al (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106(2):419–427
Honczarenko M et al (2006) Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24(4):1030–1041
Wynn RF et al (2004) A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104(9):2643–2645
Brooke G et al (2008) Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 17(5):929–940
Wang Y, Deng Y, Zhou GQ (2008) SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res 1195:104–112
Yu J et al (2010) SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal cells toward areas of heart myocardial infarction through activation of PI3K/Akt. J Cardiovasc Pharmacol 55(5):496–505
Son BR et al (2006) Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24(5):1254–1264
Wang L et al (2002) MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology 7(2):113–117
Fiedler J, Etzel N, Brenner RE (2004) To go or not to go: migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. J Cell Biochem 93(5):990–998
Schichor C et al (2006) Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 199(2):301–310
Seiffge D (1996) Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J Rheumatol 23(12):2086–2091
Schwarz D et al (2005) Host shift to an invasive plant triggers rapid animal hybrid speciation. Nature 436(7050):546–549
Ruster B et al (2006) Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108(12):3938–3944
Steingen C et al (2008) Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 44(6):1072–1084
Ip JE et al (2007) Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 18(8):2873–2882
Semon JA et al (2010) Integrin expression and integrin-mediated adhesion in vitro of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels. Cell Tissue Res 341(1):147–158
Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4(3):206–216
Veevers-Lowe J et al (2011) Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of growth factor signals. J Cell Sci 124(Pt 8):1288–1300
Cernuda-Morollon E, Gharbi S, Millan J (2010) Discriminating between the paracellular and transcellular routes of diapedesis. Methods Mol Biol 616:69–82
De Becker A et al (2007) Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 92(4):440–449
Ho IA et al (2009) Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27(6):1366–1375
Lee MH, Kwon T-G, Park HS (2009) Comparative phenotypic analysis of mesenchymal stem cells derived from bone marrow, skin, adipose tissue and umbilical cord. Tissue Eng Regener Med 6(1–3):179–185
Li SH et al (2009) Tracking cardiac engraftment and distribution of implanted bone marrow cells: comparing intra-aortic, intravenous, and intramyocardial delivery. J Thorac Cardiovasc Surg 137(5):1225–1233 e1
Bakshi A et al (2004) Minimally invasive delivery of stem cells for spinal cord injury: advantages of the lumbar puncture technique. J Neurosurg Spine 1(3):330–337
Cizkova D et al (2010) Repetitive intrathecal catheter delivery of bone marrow mesenchymal stromal cells improves functional recovery in a rat model of contusive spinal cord injury. J Neurotrauma 28(9):1951–1961
Harting MT et al (2009) Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 110(6):1189–1197
Ohtaki H et al (2008) Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 105(38):14638–14643
Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383(6603):787–793
Wan YY (2010) Multi-tasking of helper T cells. Immunology 130(2):166–171
Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19(3):281–286
Annunziato F et al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861
Bi Y, Liu G, Yang R (2007) Th17 cell induction and immune regulatory effects. J Cell Physiol 211(2):273–278
Kitchingman GR, Rooney C (1998) Cytotoxic T cells and immunotherapy. Pediatr Radiol 28(7):489–491
Campbell NA et al (2008) Biology, 8th edn. Pearson Benjamin Cummings, San Francisco
Read S, Powrie F (2001) CD4+ regulatory T cells. Curr Opin Immunol 13(6):644–649
Takahashi T et al (1998) Immunologic self-tolerance maintained by CD25 + CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10(12):1969–1980
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barminko, J., Gray, A., Maguire, T., Schloss, R., Yarmush, M.L. (2013). Mesenchymal Stromal Cell Mechanisms of Immunomodulation and Homing. In: Chase, L., Vemuri, M. (eds) Mesenchymal Stem Cell Therapy. Stem Cell Biology and Regenerative Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-200-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-62703-200-1_2
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-199-8
Online ISBN: 978-1-62703-200-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)